Royalty Table

Royalty Table

Below are the disclosed royalties Ligand currently receives or is eligible to receive based on future drug approvals. 

Product Partner Royalty Structure
Promacta® (1) (2) Novartis 4.7% – Less than $100M annual sales
6.6% – Sales in range of $100M - $200M
7.5% – Sales in range of $200M - $400M
9.4% – Sales in range of $400M - $1.5B
9.3% – Sales greater than $1.5B
Kyprolis® (1) Amgen 1.5% – Sales up to and including $250M
2.0% – Sales in range of $250M - $500M
2.5% – Sales in range of $500M - $750M
3.0% – Sales greater than $750M
Viviant™/Conbriza™ and Duavee™ (1) Pfizer 0.5% – Less than $400M annual sales
1.5% – Sales in range of $400M - $1.0B annually
2.5% – Sales greater than $1B annually
CE-Topiramate (2) CURx Pharmaceuticals 6.0% – Less than $50M annual sales
6.75% – Sales in range of $50M - $100M annually
7.5% – Sales greater than $100M annually
CE-Budesonide Sedor Pharmaceuticals 8.0% – Less than $25M annual sales
10.0% – Sales greater than $25M annually
CE-Meloxicam Sedor Pharmaceuticals 8.0% – Less than $25M annual sales
10.0% – Sales greater than $25M annually
IRAK-4 TG Therapeutics 6.0-9.5% – Royalty tiers undisclosed
CE-Lamotrigine CURx Pharmaceuticals 4.0-7.0% – Royalty tiers undisclosed
Lasofoxifene Sermonix 6.0-10.0% – Royalty tiers undisclosed
VK-0612 (FBPase Inhibitor) Viking Therapeutics 7.5-9.5% – Royalty tiers undisclosed
VK-5211 (SARM) Viking Therapeutics 7.25-9.25% – Royalty tiers undisclosed
VK-2809/VK-0214 (TRβ) Viking Therapeutics 3.5-7.5% – Royalty tiers undisclosed
Oral EPO Viking Therapeutics 4.5-8.5% – Royalty tiers undisclosed
DGAT-1 Viking Therapeutics 3.0-7.0% – Royalty tiers undisclosed
LTP-O3FA Omthera/AstraZeneca Tiered mid-to-high single digit royalties
EVOMELA™ (1) Spectrum 20.0% – All sales
Baxdela™ Melinta 2.5% – All sales
Brexanolone (SAGE-547) SAGE Therapeutics, Inc. 3.0% – All sales
Sparsentan Retrophin 9.0% – All sales
CE-Fosphenytoin Sedor Pharmaceuticals 11.0% – All sales
Pradefovir Chiva Pharmaceuticals 9.0% – All sales
MB07133 Chiva Pharmaceuticals 6.0% – All sales
KLM465 ('5921) (2) Novartis 14.5% – All sales (6.5% for first year sales)
Topical lasofoxifene Azure Biotech 5.0% – All sales
MM-121 Merrimack Pharma <1% – All sales
MM-151 Merrimack Pharma <1% – All sales
MM-141 Merrimack Pharma <1% – All sales
ME-143 MEI Pharma Low single digit royalty
ME-344 MEI Pharma Low single digit royalty
ADX-102 (NS-2) Aldeyra Therapeutics Low single digit royalty
  1. Currently receiving royalty payments
  2. Net of payments due to third parties